Kane Biotech Expanding bluestem(TM) to the USA
WINNIPEG, MANITOBA -- (Marketwired) -- 03/01/16 -- Kane Biotech Inc. (TSX VENTURE:KNE) (the "Company" or "Kane Biotech") is pleased to announce it will be launching its bluestem™ brand of premium pet oral care products at Global Pet Expo in Orlando Florida March 16th-18th.
bluestem was released to select pet specialty retailers in Canada in 2015 and quickly demonstrated a high level of response from Canadian pet parents as well as excellent sell-through rates for its retail stores. The attractiveness and close proximity of the larger US market enticed Kane Biotech to expand bluestem's availability south of the border. "We are thrilled to be showcasing our innovative, clinically proven, safe and effective bluestem products at the world's largest pet industry gathering. I personally invite all buyers attending Global Pet Expo to visit our booth, meet our team and learn more about the bluestem opportunity," says Kane Biotech CEO Mark Ahrens-Townsend.
Global Pet Expo is the pet industry's largest annual trade show, presented by the American Pet Products Association (APPA) and Pet Industry Distributors Association (PIDA). More than 6,000 buyers from over 80 countries are expected to attend this year.
bluestem oral care will be located at booth #5344 in the 'What's New!' section of the exhibition hall. Meeting invitations are extended to distributors, retailers, and industry insiders. With a new booth, product samples, and advertising support in the Global Pet Expo directory and dailies, the show is expected to be busy and productive, generating lots of new opportunities for the sale of bluestem in pet specialty stores across the US. Later this year bluestem will also exhibit at Super Zoo in Las Vegas, followed by the Canadian PIJAC show in September.
For more information about bluestem or to book a meeting at Global Pet Expo, please email Erika Linden at elinden"at"kanebiotech.com, or call her at 1-204-453-1301. As well please visit the bluestem website at www.bluestempets.com.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human and animal health problems such as tooth decay, chronic inflammatory skin disorders, recurrent urinary tract infections, chronic wounds and medical device associated infections.
Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane Biotech's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane Biotech's filings with Canadian securities regulatory authorities, as well as Kane Biotech's ability to anticipate and manage the risks associated with the foregoing. Kane Biotech cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane Biotech's forward-looking statements to make decisions with respect to Kane Biotech, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane Biotech cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane Biotech undertakes no obligation to update or revise any forward-looking statement.
StrixNB™, DispersinB®, Aledex®, bluestem™ and coactiv+™ are registered trademarks of Kane Biotech Inc. All Rights Reserved 2016
To view the image accompanying this press release, click on the following link: http://media3.marketwire.com/docs/Kane229.jpg
Image Available: http://www.marketwire.com/library/20160229-Kane229a.jpg
President & CEO
Kane Biotech Inc.
Source: Kane Biotech Inc.
Released March 1, 2016